ERBB2 Inhibition and Heart Failure
Authors:
- Gregory M. CoteGregory M. Cote
- Douglas B. SawyerDSDouglas B. Sawyer
- Bruce A. ChabnerBCBruce A. Chabner
- 29 November 2012
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (22) , 2150-2153
Abstract
The anti-ERBB2 antibody, trastuzumab, was developed to treat ERBB2-positive breast cancer. The cardiac toxicity it produced was unexpected but led to new insights about a role for ERBB2 in the response of the heart to stress.Keywords
This publication has 20 references indexed in Scilit:
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Feedback regulation of EGFR signalling: decision making by early and delayed loopsNature Reviews Molecular Cell Biology, 2011
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast CancerJournal of Clinical Oncology, 2010
- An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer CellsCancer Cell, 2010
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Neuregulins: functions, forms, and signaling strategiesExperimental Cell Research, 2003
- The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB ReceptorsMolecular Cell, 2003
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptorNature, 1995
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987